Industry Strength Score
54/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
VIKING THERAPEUTICS INC (1VKTX.MI) Stock Price & Overview
BIT:1VKTX • US92686J1060
Current stock price
27.9 EUR
-0.6 (-2.11%)
Last:
The current stock price of 1VKTX.MI is 27.9 EUR. Today 1VKTX.MI is down by -2.11%. In the past month the price increased by 19.18%.
1VKTX.MI Key Statistics
1-Month Range24.505 - 33.955
Current 1VKTX.MI stock price positioned within its 1-month range.
- Market Cap
- 3.233B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.70
- Dividend Yield
- N/A
1VKTX.MI Stock Performance
Today
-2.11%
1 Week
+10.54%
1 Month
+19.18%
3 Months
N/A
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
1VKTX.MI Stock Chart
1VKTX.MI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to 1VKTX.MI.
Chartmill TA Rating
Chartmill Setup Rating
1VKTX.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1VKTX.MI. 1VKTX.MI has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
1VKTX.MI Earnings
Next Earnings DateApr 29, 2026
Last Earnings DateFeb 11, 2026
PeriodQ4 / 2025
EPS Reported-$1.38
Revenue Reported
EPS Surprise -51.32%
Revenue Surprise %
1VKTX.MI Forecast & Estimates
25 analysts have analysed 1VKTX.MI and the average price target is 80.98 EUR. This implies a price increase of 190.26% is expected in the next year compared to the current price of 27.9.
Analysts
Analysts84.8
Price Target80.98 (190.25%)
EPS Next Y-37.93%
Revenue Next YearN/A
1VKTX.MI Financial Highlights
Over the last trailing twelve months 1VKTX.MI reported a non-GAAP Earnings per Share(EPS) of -2.7. The EPS decreased by -218% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-359.64M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.25% | ||
| ROE | -56.28% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-331.25%
Sales Q2Q%N/A
EPS 1Y (TTM)-218%
Revenue 1Y (TTM)N/A
1VKTX.MI Ownership
Ownership
Inst Owners63.48%
Shares115.89M
Float112.63M
Ins Owners2.79%
Short Float %N/A
Short RatioN/A
1VKTX.MI Industry Overview
1VKTX.MI operates in the Biotechnology sub-industry within the Health Care sector. This group contains 412 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 412
- New Highs
- 4.6%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.9%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.1
1VKTX.MI Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.81 | 41.543B | ||
| 1AE | ARGENX SE | 28.79 | 41.518B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.443B | ||
| ABVX | ABIVAX SA | N/A | 7.648B | ||
| 2X1 | ABIVAX SA | N/A | 7.64B | ||
| GLPG | GALAPAGOS NV | N/A | 1.591B | ||
| GXE | GALAPAGOS NV | N/A | 1.59B | ||
| NANO | NANOBIOTIX | N/A | 1.39B | ||
| PHARM | PHARMING GROUP NV | 47.29 | 1.011B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.01B | ||
| PHGN | PHARMING GROUP NV | 47.13 | 1.008B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 954.74M | ||
| IVA | INVENTIVA SA | N/A | 895.23M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1VKTX.MI
Company Profile
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 53 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Company Info
IPO: 2015-04-29
VIKING THERAPEUTICS INC
9920 Pacific Heights Blvd, Suite 350
San Diego CALIFORNIA US
Employees: 53
Phone: 18009279800
VIKING THERAPEUTICS INC / 1VKTX.MI FAQ
What does 1VKTX do?
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 53 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
What is the stock price of VIKING THERAPEUTICS INC today?
The current stock price of 1VKTX.MI is 27.9 EUR. The price decreased by -2.11% in the last trading session.
What is the dividend status of VIKING THERAPEUTICS INC?
1VKTX.MI does not pay a dividend.
What is the ChartMill rating of VIKING THERAPEUTICS INC stock?
1VKTX.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of VIKING THERAPEUTICS INC (1VKTX.MI) based on its PE ratio?
VIKING THERAPEUTICS INC (1VKTX.MI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.7).
What is VIKING THERAPEUTICS INC worth?
VIKING THERAPEUTICS INC (1VKTX.MI) has a market capitalization of 3.23B EUR. This makes 1VKTX.MI a Mid Cap stock.